Summary

Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032
Market Overview
In 2022, the cell and gene therapy biomanufacturing market was valued at USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market is expected to increase from USD 13.9 billion in 2023 to USD 31.2 billion by 2032, with a compound yearly growth rate (CAGR) of 10.60% over the forecast period (2024-2032). Growing investments in cell and gene therapy research are significant industry drivers, accelerating market expansion.
The rapid growth of the Cell and Gene Therapy Market drives the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. With the approval of novel cell and gene therapies and encouraging clinical trial findings, there is a growing need to increase manufacturing to satisfy commercialization demands. The market's exponential growth needs the development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure. To meet the increased demand for cell and gene therapy products, biomanufacturing businesses are investing in advanced technologies like automation, single-use systems, and closed-system bioreactors. Furthermore, market expansion is driving collaborations, partnerships, and investments in biomanufacturing capacity, which is supporting growth in the Cell and Gene Therapy Biomanufacturing Market to address the needs of the continuously changing cell and gene therapy environment.
Market Segment insights
Consumables, Equipment, and Software Solutions make up the Product Type division of the Cell and Gene Therapy Biomanufacturing Market.
Usage-based market segmentation includes Commercial Stage Manufacturing and Research Stage Manufacturing.
The market is segmented by application, which comprises upstream processing, harvesting, and downstream processing.
Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks are the end-user segments of the Cell and Gene Therapy Biomanufacturing Market.
Regional insights

The analysis covers market insights for North America, Europe, Asia-Pacific, and the rest of the world. Several reasons have contributed to North America's dominance in the Cell and Gene Therapy Biomanufacturing Market. To begin with, the region has a strong ecosystem of biotechnology and pharmaceutical businesses that are actively involved in cell and gene therapy research and development. Second, North America has well-established regulatory frameworks and supporting policies for cell and gene therapy manufacturing, which helps the market flourish.
Because of its qualified workforce, Europe has the second-largest market share in cell and gene therapy biomanufacturing. Europe has the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market due to a variety of factors. The region has a well-established biopharmaceutical industry, modern infrastructure, and a competent workforce.
The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is predicted to expand at the quickest CAGR between 2024 and 2032. The Asia Pacific region has the greatest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to a variety of factors. To begin, the region's fast expanding biopharmaceutical industry is being pushed by increased investment in R&D, particularly in cell and gene therapy.
Major Players
The Cell and Gene Therapy Biomanufacturing market is dominated by Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. SCOPE OF THE STUDY
2.2.1. RESEARCH OBJECTIVE
2.2.2. ASSUMPTIONS
2.2.3.LIMITATIONS
3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING MODEL
3.6. MARKET SIZE ESTIMATION
3.6.1. BOTTOM-UP APPROACH
3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION
4. MARKET DYNAMICS
4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES
5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.2. PORTER’S FIVE FORCES ANALYSIS
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. MARKET IMPACT ANALYSIS
5.3.2. REGIONAL IMPACT
5.3.3. OPPORTUNITY AND THREAT ANALYSIS
6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONSUMABLES
6.3. EQUIPMENT
6.4. SOFTWARE SOLUTIONS
7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE
7.1. OVERVIEW
7.2. COMMERCIAL STAGE MANUFACTURING
7.3. RESEARCH STAGE MANUFACTURING
8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. UPSTREAM PROCESSING
8.3. HARVESTING
8.4. DOWNSTREAM PROCESSING
9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER
9.1. OVERVIEW
9.2. LIFE SCIENCE COMPANIES
9.3. CONTRACT RESEARCH ORGANIZATIONS
9.4. CONTRACT MANUFACTURING ORGANIZATIONS
9.5. CELL BANKS
10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION
10.1. OVERVIEW
10.1. NORTH AMERICA
10.1.1. US
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. FRANCE
10.2.3. UK
10.2.4. ITALY
10.2.5. SPAIN
10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. AUSTRALIA
10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
10.4.1. MIDDLE EAST
10.4.2. AFRICA
10.4.3. LATIN AMERICA
11. COMPETITIVE LANDSCAPE
11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
11.7.2. MERGER & ACQUISITIONS
11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
11.8.1. SALES & OPERATING INCOME, 2023
11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023
12. COMPANY PROFILES
12.1. LONZA GROUP
12.1.1. COMPANY OVERVIEW
12.1.2. FINANCIAL OVERVIEW
12.1.3. PRODUCTS OFFERED
12.1.4. KEY DEVELOPMENTS
12.1.5. SWOT ANALYSIS
12.1.6. KEY STRATEGIES
12.2. THERMO FISHER SCIENTIFIC INC.
12.2.1. COMPANY OVERVIEW
12.2.2. FINANCIAL OVERVIEW
12.2.3. PRODUCTS OFFERED
12.2.4. KEY DEVELOPMENTS
12.2.5. SWOT ANALYSIS
12.2.6. KEY STRATEGIES
12.3. MERCK KGAA
12.3.1. COMPANY OVERVIEW
12.3.2. FINANCIAL OVERVIEW
12.3.3. PRODUCTS OFFERED
12.3.4. KEY DEVELOPMENTS
12.3.5. SWOT ANALYSIS
12.3.6. KEY STRATEGIES
12.4. WUXI APPTEC
12.4.1. COMPANY OVERVIEW
12.4.2. FINANCIAL OVERVIEW
12.4.3. PRODUCTS OFFERED
12.4.4. KEY DEVELOPMENTS
12.4.5. SWOT ANALYSIS
12.4.6. KEY STRATEGIES
12.5. CATALENT, INC.
12.5.1. COMPANY OVERVIEW
12.5.2. FINANCIAL OVERVIEW
12.5.3. PRODUCTS OFFERED
12.5.4. KEY DEVELOPMENTS
12.5.5. SWOT ANALYSIS
12.5.6. KEY STRATEGIES
12.6. SAMSUNG BIOLOGICS
12.6.1. COMPANY OVERVIEW
12.6.2. FINANCIAL OVERVIEW
12.6.3. PRODUCTS OFFERED
12.6.4. KEY DEVELOPMENTS
12.6.5. SWOT ANALYSIS
12.6.6. KEY STRATEGIES
12.7. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
12.7.1. COMPANY OVERVIEW
12.7.2. FINANCIAL OVERVIEW
12.7.3. PRODUCTS OFFERED
12.7.4. KEY DEVELOPMENTS
12.7.5. SWOT ANALYSIS
12.7.6. KEY STRATEGIES
12.8. CHARLES RIVER LABORATORIES
12.8.1. COMPANY OVERVIEW
12.8.2. FINANCIAL OVERVIEW
12.8.3. PRODUCTS OFFERED
12.8.4. KEY DEVELOPMENTS
12.8.5. SWOT ANALYSIS
12.8.6. KEY STRATEGIES
12.9. CYTIVA
12.9.1. COMPANY OVERVIEW
12.9.2. FINANCIAL OVERVIEW
12.9.3. PRODUCTS OFFERED
12.9.4. KEY DEVELOPMENTS
12.9.5. SWOT ANALYSIS
12.9.6. KEY STRATEGIES
12.10. NOVASEP
12.10.1. COMPANY OVERVIEW
12.10.2. FINANCIAL OVERVIEW
12.10.3. PRODUCTS OFFERED
12.10.4. KEY DEVELOPMENTS
12.10.5. SWOT ANALYSIS
12.10.6. KEY STRATEGIES
13. APPENDIX
13.1. REFERENCES
13.2. RELATED REPORTS